INTRODUCTION {#S1}
============

Iron-sulfur (Fe-S) clusters (ISCs) are small inorganic cofactors of metalloproteins found in bacteria and eukaryotes that are indispensable for cellular processes such as respiration, protein translation, purine metabolism, DNA repair and gene expression regulation.^[@R1]--[@R3]^ IscA proteins are highly conserved and fundamental to the physiology of prokaryotes and eukaryotes. Loss of function of several Fe-S cluster assembly components have been known to result in human diseases including multiple mitochondrial dysfunctions syndromes (MMDS).^[@R4]--[@R7]^

Currently four types, MMDS1 (MIM \#605711), MMDS2 (MIM \#614299), MMDS3 (MIM \#615330) and MMDS4 (MIM \#616370) have been mapped to *NFU1* (MIM \#608100), *BOLA3* (MIM \#613183), *IBA57* (MIM \#615316) and *ISCA2* (MIM \#615317) respectively. All MMDS share variable neurodevelopmental delay, regression, seizures, lactic acidosis and leukodystrophy resulting in early death of affected individuals.^[@R4],\ [@R8]--[@R10]^ Here we report another likely MMDS resulting from a biallelic mutation in *ISCA1*, a key component of the Fe-S biogenesis process, from two unrelated Indian families.

MATERIALS AND METHODS {#S2}
=====================

Patients {#S3}
--------

Family 1 consulted us for prenatal counseling. They were in a consanguineous marriage and had two healthy daughters and lost two children ([Figure 1A](#F1){ref-type="fig"}). Both P1 and P2 had normal birth and antenatal history followed by inconsolable cry and feeding difficulties since newborn period. Both of them did not achieve any other developmental milestone except partial head control at 3 months of age. P1 and P2 developed seizures at the age of 5 months and 4 months respectively followed by progressive neurological deterioration and spasticity. P1 died at 1 year and 7 months while P2 succumbed at 5 years of age. Stored DNA was obtained for patient P2 and blood samples were obtained for parents and healthy children. Brain imaging of both children showed pachygyria, extensive cerebral and cerebellar white matter disease and dilated cerebral ventricles. Increased lipid lactate peak was seen on magnetic resonance spectroscopy of brain in P1 ([Figure 1B](#F1){ref-type="fig"}). Normal hematological and biochemical investigations were noted except for elevated creatinine phosphokinase in P2.

Family 2 was ascertained from our in-house exome data for children with neurodevelopmental disorders. P3 and P4 ([Figure 1C](#F1){ref-type="fig"}) were born to non-consanguineous couple and were asymptomatic till first two months of life. They did not achieve any developmental milestones. Seizures developed at the age of 3 months and 2 months in P3 and P4 respectively following which neurologic deterioration was noted in them. P3 had lactic acidosis and white matter disease was documented in medical records of P3 on computed tomography of brain. P4 had extensive leukodystrophy involving cerebral and cerebellar white matter with dilated ventricles. Magnetic resonance spectroscopy showed elevated lipid lactate peak in her brain ([Figure 1D](#F1){ref-type="fig"}). They succumbed to the disease at the age of 11 months and 2 years 3 months respectively. Complete clinical details for both families are provided in [Table 1](#T1){ref-type="table"}.

This research work has the approval of the institutional ethics committee. Specific parental informed consent was obtained for the use of photographs, clinical and research findings for publication.

Whole exome sequencing {#S4}
----------------------

Whole exome sequencing (WES) was carried out as described previously to achieve an average coverage depth of 100--130×, such that \~95% of the bases are covered at \>20x, with a sensitivity of \>90%.^[@R11]^ WES raw data was processed using SeqMule and the called variants were annotated with ANNOVAR.^[@R12],\ [@R13]^ The overall variant filtering strategy is outlined in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}.

Homozygosity mapping {#S5}
--------------------

Using FILTUS software, homozygosity mapping was performed for both the probands with default input file settings while loading the exome VCF files.^[@R14]^ The minimum segment threshold and the posterior threshold parameters were set to 3Mb and 0.5 respectively for running the AutEx algorithm, that is built on the method of hidden Markov model for detecting the autozygous regions.^[@R15]^

Protein modeling {#S6}
----------------

Structures of wild-type and mutant p.(Glu87Lys) human ISCA1 protein (UniProt accession: Q9BUE6) was predicted using the online web-server SWISS-MODEL (<https://swissmodel.expasy.org/>).^[@R16]^ Multiple sequence alignment was performed using Clustal Omega.^[@R17]^ Amino acid conservation was also evaluated using the ConSurf server (<http://consurf.tau.ac.il/2016/>).^[@R18]^

RESULTS {#S7}
=======

We ascertained two families with two affected children each with a neurodevelopmental disorder. The phenotype mainly consists of early onset progressive neurodegeneration, seizures, extensive white matter disease and elevated lactate levels. A non-synonymous missense pathogenic variation, c.259G\>A \[p.(Glu87Lys)\] in *ISCA1* (NM_030940.3) in the homozygous state was found in family 1 (ClinVar accession SCV000328646). The same variant was also observed in proband P4 of family 2 from the in-house exome sequencing data ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}). The variant was validated by Sanger sequencing in affected subjects from both families (upper panel in [Figure 1E](#F1){ref-type="fig"}, [1F](#F1){ref-type="fig"}). Targeted testing of parents and healthy siblings in both the families using Sanger sequencing confirmed the variation to be heterozygous in them (middle and lower panel in [Figure 1E](#F1){ref-type="fig"}, [1F](#F1){ref-type="fig"}). Unaffected sibs in family 1 were heterozygous carriers of the variant.

The p.(Glu87Lys) variant of ISCA1 reported here is not present in a homozygous state in 1000 Genomes project, the Exome Variant Server, CentoMD and in our in-house exome data of 139 unrelated individuals from the local population. However, it is present in the heterozygous state in 1/118662 individuals (AF = 0.000008427) in ExAC database. *ISCA1* has a positive Z score (z = 1.29) for missense constraint in ExAC database, which embodies its intolerance to variations. In the recently made available gnomAD browser,^[@R19]^ the variant p.(Glu87Lys) is observed in heterozygous state in a single individual out of 240,238 (AF = 0.000004163). This variant appears to have an impact on the functional Fe-S biogenesis domain of ISCA1 ([Supplementary Figure S1B](#SD1){ref-type="supplementary-material"}), at a residue that is highly conserved, as indicated by Clustal Omega multiple sequence alignment ([Figure 1G](#F1){ref-type="fig"}) and ConSurf ([Figure 2A](#F2){ref-type="fig"}, [2B](#F2){ref-type="fig"}, [2C](#F2){ref-type="fig"}), with a PhyloP score of 7.442. This was further supported by Position Specific Evolutionary Preservation (PANTHER-PSEP)^[@R20]^ analysis that predicts this SNV to be probably damaging. Several functional in silico prediction tools were also used to interrogate the damaging consequences of the p.(Glu87Lys) variation. It was also predicted to be highly deleterious with a CADD score of 22.5.^[@R21]^ Screening for Nonacceptable Polymorphisms (SNAP2)^[@R22],\ [@R23]^, a web-based tool that combines a variety of information pertaining to evolutionary conservation, secondary structure and solvent accessibility of the protein predicted the p.(Glu87Lys) variant to have a severe detrimental effect with a score of 80 and accuracy of 91%.

Since the two probands are of Indian origin, from the same geographic location (family 1 was consanguineous and family 2 denied any consanguinity) and the same pathogenic variant is identified in both of them, we explored the possibility of a founder effect. After examining the homozygous regions around the *ISCA1* variant in both the probands, generated by the exome sequencing data, we identified only one overlapping region of homozygosity (ROH) spanning 3.3 Mb in chromosome 9 (Chr9: 85613354-88925774) flanking the variant ([Supplementary Figure S3](#SD1){ref-type="supplementary-material"}).

We used 3D protein modeling to assess the structural impact of the replacement of native acidic Glu87 by the mutant basic Lys87 residue ([Figure 2A--C](#F2){ref-type="fig"}). The human *ISCA1* gene encodes for a 129 amino acid product involved in the biogenesis of iron--sulfur (Fe-S) clusters and contains a conserved C-terminal HESB signature. The missense substitution p.(Glu87Lys) occurs at a highly conserved residue in the essential functional domain for Fe-S biogenesis in the ISCA1 protein ([Supplementary Figure S1B](#SD1){ref-type="supplementary-material"}). HOPE and ConSurf analyses indicated salt-bridge formation between Glu87 and Lys49 residues in wild-type ISCA1, which is lost in the mutant ([Figure 2B](#F2){ref-type="fig"} and [Figure 2C](#F2){ref-type="fig"}). VADAR analysis predicted that the side-chain Hydrogen bonding interaction of Glu87 with Ser73 and Lys88 are potentially lost in the ISCA1 mutant. Analyses of protein stability via I-Mutant (score 7) and Eris web-server (score 0.64 ΔΔG kcal/mol) are also consistent in predicting that this variant leads to destabilization of ISCA1 protein. Detailed results of protein modeling are available as a [supplementary note in supplementary data](#SD1){ref-type="supplementary-material"}.

DISCUSSION {#S8}
==========

We describe two independent families, both with two affected children each, with a severe neurodevelopmental disorder associated with a homozygous c.259G\>A variant in *ISCA1*. The major clinical features include severe neurodevelopmental delay, seizures, spasticity and regression of milestones. Extensive leukodystrophy, lactate peaks and ventricular dilatation were observed on magnetic resonance imaging of brain. We note the phenotype observed in all affected subjects in both families is similar to that previously described for all four types of MMDS ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). Neuronal migrational abnormalities seen in both children in Family 1 has not been previously described in other subtypes of MMDS. Pigmentary retinopathy, impaired hearing and vision, elevated creatine kinase, lactic acidosis are other likely features of this condition, usually considered to suggest a mitochondrial disease.

In addition, *ISCA1* was observed in the only common ROH in the two families suggesting the possibility of a founder mutation in the local population ([Supplementary Table S3 and Supplementary Table S4](#SD1){ref-type="supplementary-material"}). The genes within the shared region are given in [Supplementary Table S5](#SD1){ref-type="supplementary-material"}.

The Fe-S protein biogenesis in eukaryotes occurs in mitochondria, cytosol, or nucleus and is carried out in two steps. The first step is the formation of \[2Fe-2S\] cluster by proteins forming the core ISC assembly components. This cluster is transferred to monothiol glutaredoxin 5 (GRX5), which acts as a Fe/S cluster transfer protein inserting the \[2Fe-2S\] cluster into mitochondrial \[2Fe- 2S\]-requiring proteins. The second step involves the generation of \[4Fe-4S\] components and their integration into the required metalloproteins ([Supplementary Figure S1A](#SD1){ref-type="supplementary-material"}). Unlike the core ISC assembly components, proteins mediating the second step are not involved in formation of mitochondrial \[2Fe-2S\] and cytosolic \[4Fe-4S\] clusters.^[@R24],\ [@R25]^ This delivery step requires highly conserved and functionally non-redundant A-type ISC proteins, ISCA1 and ISCA2 in eukaryotes.^[@R26]^ Pathogenic variations in genes encoding for several components of this machinery, *NFU1, BOLA3, IBA57* and *ISCA2* are already implicated in causing four types of multiple mitochondrial dysfunctions syndromes MMDS.

Additionally, we note that the deleterious nature of this variation is suggested by its occurrence at residue 87 that lies within a region of 48--90 residues of ISCA1, delineated previously to be instrumental for mediating ISCA1 interaction with IOP1 (iron-only hydrogenase-like protein 1), that plays a role in cytosolic Fe-S protein assembly pathway.^[@R27]^ Our protein structural analyses are also consistent in predicting that the missense substitution Glu87Lys has severe consequences disrupting crucial molecular interactions, reducing protein stability and is likely debilitating for ISCA1 function.

To conclude, the existing literature on the diseases caused by pathogenic variants in various components of Fe-S biogenesis pathway, *in silico* functional analyses, structural modeling predictions, founder effect, the common phenotype in all affected subjects from two families, which is similar to that described in all four types of MMDS that occur due to mutations in genes encoding proteins involved in Fe-S biogenesis, strongly suggest that the presently reported *ISCA1* variant likely results in another MMDS. Early demise of patients limited our access to cell lines for further functional studies.

Supplementary Material {#S9}
======================
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![(A) Pedigree of Family 1. (B) Brain MRI images of family 1, P1 and P2. (a,b) T2 weighted MRI shows pachygyria (arrowhead), moderate dilatation of the ventricles (white arrows) and diffuse T2 hyperintensity in the cerebral and cerebellar white matter (black arrows) and posterior limb of internal capsule in P1 at 6 months. (c) MRI performed for the same child at 9 months shows myelination abnormality involving the medulla and the cervical cord (white arrows) in the white matter suggestive of delayed myelination and (d) MR spectroscopy shows increased lipid-lactate peaks. (e,f) T2 weighted MRI in P2 shows pachygyria (arrowhead), moderate dilatation of the ventricles (white arrows) and diffuse T2 hyperintensity (black arrows) at the age of 5 months. (C) Pedigree of Family 2. (D) Brain MRI images of family 2, P4. (a--c) T2 weighted MRI in P4 shows diffuse T2 hyperintensity in the cerebral and cerebellar white matter (black arrows), dilated ventricles (white arrows) with (d) raised lipid-lactate peaks on MR spectroscopy at the age 1 year 11 months, consistent with dysmyelination. (E,F) Sanger validation of the ISCA1 variant in family 1 and 2. The pathogenic variation c.259G\>A of ISCA1 is found in homozygous state in (upper panel) probands of family 1 and 2 and is heterozygous in their parents (middle and lower panel). (G) Comparison of ISCA1 orthologs from H. sapiens, R. norvegicus, M. musculus, P. anubis, G. gorilla, D. rerio, A. thaliana and C. elegans reveals the high conservation of the Glu87 residue (highlighted in red).](nihms856833f1){#F1}

![(A) Protein structure prediction shows replacement of (a,b) the native glutamic acid residue that has an acidic side-chain with (c) lysine bearing a basic side-chain. Color spectrum indicates high conservation for the Glu87 residue. (B) Predicted salt-bridge formation between Glu87 and Lys49 where the distance between the hydrogen donor atom (NZ) of Lys49 and the hydrogen acceptor atom (OE1) of Glu37 is 3.66 Å. (C) Replacement of the Glu87 with mutant Lys87 is predicted to lead to the loss of the salt-bridge between the native residue and Lys49. (D,E)](nihms856833f2){#F2}

###### 

Clinical findings observed in our patients.

  Clinical Findings                                  Family 1                                         Family 2
  -------------------------------------------------- ------------------------------------------------ -----------------------------
  Individual                                         P2                                               P4
  Origin                                             Indian                                           Indian
  Sex                                                Male                                             Female
  Age at assessment                                  8 months                                         1 year 11 months
  Age at demise                                      5 years                                          2 years 3 months
  Coding DNA change                                  c.259G\>A                                        c.259G\>A
  Amino acid change                                  p.E87K                                           p.E87K
  Zygosity                                           Homozygous                                       Homozygous
  Exon                                               4                                                4
  Birth weight (gm/SD)                               3600/−1                                          2700/−1
  **Anthropometry**                                                                                   
  Weight (gm/SD)                                     NA                                               5800/−6
  Length (cm/SD)                                     NA                                               76/−5
  OFC (cm/SD)                                        42/−2                                            43.5/−6
  **Neurological abnormalities**                                                                      
  Seizures                                           \+                                               \+
  Onset of seizures                                  4 months                                         2 months
  Developmental delay                                \+                                               \+
  Milestones achieved                                Partial head control                             No milestones achieved
  Feeding difficulty                                 \+                                               \+
  Neurological deterioration                         \+                                               \+
  Tone                                               Spasticity                                       Spasticity
  Deep tendon reflexes                               Exaggerated                                      Exaggerated
  Strabismus                                         −                                                \+
  Other clinical findings                            History of incessant cry, tremors in the hands   −
  **MRI findings**                                                                                    
  Pachygyria                                         \+                                               −
  Cerebral white matter                              Leukodystrophy                                   Leukodystrophy
  Cerebellar white matter                            Leukodystrophy                                   Leukodystrophy
  Cerebral ventriculomegaly                          \+                                               \+
  MRS findings                                       Elevated lipid-lactate peak                      Elevated lipid-lactate peak
  EEG findings                                       NA                                               Normal
  Ophthalmological findings                          Stippled pigmentation of fundus                  NA
  Hearing evaluation                                 NA                                               Normal
  Blood lactate (mg/dl)                              36                                               40.5
  CPK (IU/L)                                         568                                              42
  Hematology                                         Normal                                           Normal
  Renal function tests                               Normal                                           Normal
  Liver function tests                               Normal                                           Normal
  Metabolic profile[1](#TFN2){ref-type="table-fn"}   Normal                                           NA

**Abbreviations:** NA: not available; +: present; −: absent; CPK: creatine phosphokinase; EEG: electroencephalogram; MRI: Magnetic resonance imaging; MRS:Magnetic Resonance spectroscopy; OFC: occipitofrontal circumference; SD: standard deviation;

Metabolic profile: serum amino acids, urine organic acids and serum carnitine profiles
